(VIANEWS) – MEDISTIM (MEDI.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| MEDISTIM (MEDI.OL) | kr265.00 | 1.61% | 31.89% |
| TUBIZE-FIN (TUB.BR) | €69.20 | 1.18% | 4.93% |
| SARTORIUS STED BIO (DIM.PA) | €220.20 | 0.62% | 32.37% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. MEDISTIM (MEDI.OL)
1.61% Forward Dividend Yield and 31.89% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.14.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 43.16. Meaning, the purchaser of the share is investing kr43.16 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.89%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 17.7% and positive 11.1% for the next.
Sales Growth
MEDISTIM’s sales growth is 15.7% for the ongoing quarter and 16.7% for the next.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MEDISTIM’s stock is considered to be overbought (>=80).
More news about MEDISTIM.
2. TUBIZE-FIN (TUB.BR)
1.18% Forward Dividend Yield and 4.93% Return On Equity
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.91.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 36.23. Meaning, the purchaser of the share is investing €36.23 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.93%.
Volatility
TUBIZE-FIN’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.44%, a negative 0.19%, and a positive 1.22%.
TUBIZE-FIN’s highest amplitude of average volatility was 1.44% (last week), 1.69% (last month), and 1.22% (last quarter).
Moving Average
TUBIZE-FIN’s worth is below its 50-day moving average of €75.27 and below its 200-day moving average of €72.80.
Volume
Today’s last reported volume for TUBIZE-FIN is 11649 which is 80.18% above its average volume of 6465.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, TUBIZE-FIN’s stock is considered to be overbought (>=80).
More news about TUBIZE-FIN.
3. SARTORIUS STED BIO (DIM.PA)
0.62% Forward Dividend Yield and 32.37% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €7.8.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 28.23. Meaning, the purchaser of the share is investing €28.23 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.37%.
Moving Average
SARTORIUS STED BIO’s value is way under its 50-day moving average of €254.78 and way below its 200-day moving average of €303.05.
Revenue Growth
Year-on-year quarterly revenue growth declined by 15.8%, now sitting on 3.36B for the twelve trailing months.
More news about SARTORIUS STED BIO.
